Identification of small-molecule inhibitors of ricin and shiga toxin using a cell-based high-throughput screen

Toxicon

Volumn 56, Issue 3, 2010, Pages 313-323

  Wahome, Paul G ^a   Bai, Yan ^b   Neal, Lori M ^a   Robertus, Jon D ^b   Mantis, Nicholas J ^a  

^a WADSWORTH CENTER   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Biodefense; High throughput screen; Therapeutic; Toxin

Indexed keywords

2 [(5E) 5[[5 (AZEPAN 1 YL)FURAN 2 YL]METHYLIDENE] 2,4 DIOXO 1,3 THIAZOLIDIN 3 YL]PROPANOIC ACID METHYL ESTER; 2 METHYLSULFONYL 1 (NAPHTHALEN 1 YLMETHYL)BENZIMIDAZOLE; 3 (5 METHYLFURAN 2 YL) N (1,2,3,4 TETRAHYDRONAPHTHALEN 1 YL)PROP 2 ENAMIDE; 4 FLUOROPHENYL METHYL 2 (FURAN 2 YL)QUINOLINE 4 CARBOXYLATE; 4,6 BIS(PROPAN 2 YLAMINO) 1,3,5 TRIAZINE 2 CARBONITRILE; ANTITOXIN; CID 1300461; CID 16271106; CID 18576762; CID 2399297; CID 5737931; CID 644401; CID 7531223; LUCIFERASE; RICIN; SHIGA TOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROTECTION; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; HIGH THROUGHPUT SCREENING; IC 50; IN VITRO STUDY; INHIBITION KINETICS; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; STRUCTURE ACTIVITY RELATION; VERO CELL;

ANTITOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; RICIN; SHIGA TOXIN;

EUKARYOTA;

EID: 77954141743     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2010.03.016     Document Type: Article

References (51)

1. Abagyan R.A., Totrov M., Kuznetsov D. ICM-a new method for protein modeling and design: applications to docking and structure prediction from the disordered native conformation. J. Comput. Chem. 1994, 15:488-506.
2. Audi J., Belson M., Patel M., Schier J., Osterloh J. Ricin poisoning. JAMA 2005, 294:2342-2351.
3. Baenziger J.U., Fiete D. Structural determinants of Ricinus communis agglutinin and toxin specificity for oligosaccharides. J. Biol. Chem. 1979, 254:9795-9799.
4. Bai Y., Monzingo A.F., Robertus J.D. The X-ray structure of ricin A chain with a novel inhibitor. Arch. Biochem. Biophys 2009, 483:23-28.
5. Calderwood S.B., Auclair F., Donohue-Rolfe A., Keusch G.T., Mekalanos J.J. Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli. PNAS 1987, 84:4364-4368.
6. Centers for Disease Control and Prevention Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC strategic planning workgroup. MMWR Morb. Mortal. Wkly. Rep. 2000, 49:1-14.
7. Centers for Disease Prevention and Control Investigation of a ricin-containing envelope at a postal facility - South Carolina. MMWR Morb. Mortal. Wkly. Rep. 2003, 52:1129-1131.
8. Challoner K.R., McCarron M.M. Castor bean intoxication: review of reported cases. Ann. Emerg. Med. 1990, 19:1177-1183.
9. Chen X.Y., Link T.M., Schramm V.L. Ricin A-chain: kinetics, mechanism, and RNA stem-loop inhibitors. Biochemistry 1998, 37:11605-11613.
10. Coan K.E., Maltby D.A., Burlingame A.L., Shoichet B.K. Promiscuous aggregate-based inhibitors promote enzyme unfolding. J. Med. Chem. 2009, 52:2067-2075.
11. Crompton R., Gall D. Georgi Markov: death in a pellet. Med. Leg. J. 1980, 48:51-62.
12. DeLano W.L. The PyMOL Molecular Graphics System 2002, DeLano Scientific, San Carlos, CA.
13. Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 1988, 171:45-50.
14. Endo Y., Tsurugi K. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J. Biol. Chem. 1987, 262:8128-8130.
15. Endo Y., Tsurugi K. The RNA N-glycosidase activity of ricin A-chain: the characteristics of the enzymatic activity of ricin A-chain with ribosomes and with rRNA. J. Biol. Chem. 1988, 263:8735-8739.
16. Fraser M.E., Chernaia M.M., Kozlov Y.V., James M.N.G. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5Å resolution. Nature Struct. Biol. 1994, 1:59-64.
17. Gonzalez T.V., Farrant S.A., Mantis N.J. Ricin induces IL-8 secretion from human monocyte/macrophages by activating the p38 MAP kinase pathway. Mol. Immunol 2006, 43:1920-1923.
18. Hughes J.N., Lindsay C.D., Griffiths G.D. Morphology of ricin and abrin exposed endothelial cells is consistent with apoptotic cell death. Hum. Exp. Toxicol. 1996, 15:443-451.
19. Jones G., Willett P., Glen R.C., Leach A.R., Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267:727-748.
20. Katzin B.J., Collins E.J., Robertus J.D. The structure of ricin A chain at 2.5Å. Proteins 1991, 10:251-259.
21. Klausner R.D., Donaldson J.G., Lippincott-Schwartz J. Brefeldin A: insights into the control of membrane traffic and organelle structure. J. Cell Biol. 1992, 116:1071-1080.
22. Kwok J.M.-M., Myatt S.S., Marson C.M., Coombes R.C., Constantinidou D., Lam E.W.-F. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol. Cancer Ther. 2008, 7:2022-2032.
23. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44:235-249.
24. Malo N., Hanley J.A., Cerquozii S., Pelletier J., Nadon R. Statistical practice in high-throughput screening data analysis. Nat. Biotechnol. 2006, 24:167-175.
25. Mantis N.J. Vaccines against the category B toxins: Staphylococcal enterotoxin B, epsilon toxin and ricin. Adv. Drug Deliv. Rev. 2005, 57:1424-1439.
26. McGovern S.L., Caselli E., Grigorieff N., Shoichet B.K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 2002, 45:1712-1722.
27. Miller D.J., Ravikumar K., Shen H., Suh J.-K., Kerwin S.M., Robertus J.D. Structure-based design and characterization of novel platforms for ricin and Shiga toxin inhibition. J. Med. Chem. 2002, 45:90-98.
28. Mlsna D., Monzingo A.F., Katzin B.J., Ernst S., Robertus J.D. Structure of recombinant ricin A chain at 2.3Å. Protein Sci. 1993, 2:429-435.
29. Montfort W., Villafranca J.E., Monzingo A.F., Ernst S.R., Katzin B., Rutenber E., Nuyhen H.X., Hamlin R., Robertus J.D. The three-dimensional structure of ricin at 2.8Å. J. Biol. Chem. 1987, 262:5398-5403.
30. Monzingo A.F., Robertus J.D. X-ray analysis of substrate analogs in the ricin A-chain active site. J. Mol. Biol. 1992, 227:1136-1145.
31. Neal, L.M., O'Hara, J., Brey, R.N. 3rd., Mantis, N.J., 2010. A monoclonal IgG antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin. 78, 552-561.
32. Noah J.W., Severson W., Noah D.L., Rasmussen L., White E.L., Jonsson C.B. A cell based luminescence assay is effective for high-throughput screening of potential antivirals. Antiviral Res. 2007, 73:50-59.
33. Ong E.B., Shaw E., Schoellmann G. The identification of the histidine residue at the active center of chymotrypsin. J. Biol. Chem. 1965, 240:694-698.
34. Quiňones B., Massey S., Friedman M., Swimley M.S., Teter K. Novel cell-based method to detect Shiga toxin 2 from Escherichia coli O157:H7 and inhibitors of toxin activity. Appl. Environ. Microbiol. 2009, 75:1410-1416.
35. Robertus J.D., Yan X., Ernst S., Monzingo A., Worley S., Day P., Hollis T., Svinth M. Structural analysis of ricin and implications for inhibitor design. Toxicon 1996, 34:1325-1334.
36. Rutenber E., Katzin B.J., Collins E.J., Mlsna D., Ernst S.E., Ready M.P., Robertus J.D. The crystallographic refinement of ricin at 2.5Å resolution. Proteins 1991, 10:240-250.
37. Saenz J.B., Doggett T.A., Haslam D.B. Identification and characterization of small molecules that inhibit intracellular toxin transport. Infect. Immun. 2007, 75:4552-4561.
38. Sandvig K., van Deurs B. Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives. EMBO J 2000, 19:5943-5950.
39. Sandvig K., Grimmer S., Lauvrak S.U., Torgersen M.L., Skretting G., van Deurs B., Iversen T.G. Pathways followed by ricin and Shiga toxin into cells. Histochem. Cell Biol. 2002, 117:131-141.
40. Seidler J., McGovern S.L., Doman T.N., Shoichet B.K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 2003, 46:4477-4486.
41. Serna A., Boedeker E.C. Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections. Curr. Opin. Gastroenterol. 2008, 24:38-47.
42. Severson W.E., McDowell M., Ananthan S., Chung D.H., Rasmussen L., Sosa M.I., White E.L., Noah J., Jonsson C.B. High-throughput screening of a 100,000-compound library for inhibitors of influenza A virus (H3N2). J. Biomol. Screen 2008, 13:879-887.
43. Shoichet B.K. Virtual screening of chemical libraries. Nature 2004, 432:862-865.
44. Strockbine N.A., Jackson M.P., Sung L.M., Holmes R.K., O'Brien A.D. Cloning and sequencing of the genes for Shiga toxin from Shigella dysenteriae type 1. J. Bacteriol. 1988, 170:1116-1122.
45. Tetko I.V., Gasteiger J., Todeschini R., Mauri A., Livingstone D., Ertl P., Palyulin V.A., Radchenko E.V., Zefirov N.S., Makarenko A.S., Tanchuk V.Y., Prokopenko V.V. Virtual computational chemistry laboratory-design and description. J. Comput-Aided Mol. Des 2005, 19:453-463.
46. Waring P., Eichner R.D., Müllbacher A. The chemistry and biology of the immunomodulating agent gliotoxin and related epipolythiodioxopiperazines. Med. Res. Rev. 1988, 8:499-524.
47. Weisblum B., Demohn V. Thiostrepton, an inhibitor of 50S ribosome subunit function. J. Bacteriol. 1970, 101:1073-1075.
48. Yan X., Hollis T., Svinth M., Day P., Monzingo A.F., Milne G.W., Robertus J.D. Structure-based identification of a ricin inhibitor. J. Mol. Biol. 1997, 266:1043-1049.
49. Yoder J.M., Aslam R.U., Mantis N.J. Evidence for widespread epithelial damage and coincident production of monocyte chemotactic protein 1 in a murine model of intestinal ricin intoxication. Infect. Immun. 2007, 75:1745-1750.
50. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J. Biomol. Screen 1999, 4:67-73.
51. Zhao L., Haslam D.B. A quantitative and highly sensitive luciferase-based assay for bacterial toxins that inhibit protein synthesis. J. Med. Microbiol. 2005, 54:1023-1030.